BioTech IP Review

Spatially Encoded Biological Assays

U.S. Patent No. 11,008,607 B2

Issued: May 18, 2021
Assignee: Likely assigned to parties involved in spatial genomics (the underlying family includes foundational work on spatially encoded assays that Illumina has been engaged with for spatial biology tools)
Focus: Technologies for highly multiplexed spatial biological assays that map biomolecules within tissue samples.

What This Patent Covers

This patent describes an assay system capable of high‑throughput spatial analysis of biological molecules (e.g., DNA, RNA, proteins) in a sample by:

  • Delivering encoded probes to defined spatial locations in a biological sample (e.g., a tissue section). Each probe has a coding tag that identifies where it was delivered.
  • Interacting probes with biological targets at multiple sites, then separating and detecting only those probes that bind to targets of interest.
  • Decoding the location and identity of targets by sequencing the probes, thus generating a “spatial map” of multiple biological targets and their abundance across the sample.

In essence, this invention allows researchers to obtain high‑resolution spatial maps of gene expression or protein localization within tissues by combining multiplexed detection with encoding schemes that record spatial position.

Why It’s Important

1. Enables Next‑Generation Spatial Biology Tools

Spatially encoded assays are foundational to spatial transcriptomics and proteomics — methods that let scientists see which genes are active and where in a tissue. This is crucial for understanding complex diseases like cancer, where cell location matters for diagnosis and therapy.

2. Powers High‑Value Research Platforms

This patent provides IP protection for technologies that underpin multiplexed biological assays used in research and clinical labs — systems that can simultaneously profile thousands of biological features across spatial regions. Such tools are core to precision medicine, drug development, and biomarker discovery.

3. Strategic Competitive Positioning

Illumina and other genomics companies are actively building spatial biology platforms — a fast‑growing segment of the biotech tools market. Patents like this help secure priority in a competitive IP landscape, especially as spatial omics becomes integrated into routine research workflows.

4. Legal and Market Impact

This patent family has been significant enough that competitors (like 10x Genomics and others) have engaged in patent disputes over spatial and single‑cell technologies, highlighting how valuable spatial assay IP is in the genomics ecosystem.

Summary

  • Patent: U.S. Patent No. 11,008,607 B2
  • Issued: May 18, 2021
  • Focus: Spatially encoded biological assays that map multiple biological targets across tissue samples using encoded probes and sequencing
  • Importance: Anchors IP in spatial transcriptomics/omics technologies, enabling high‑resolution analysis essential for advanced research and clinical biotech applications — a strategic asset in the genomics tools market.

Leave a comment